Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Celldex Therapeutics buy Guggenheim

Celldex Therapeutics
Start price
€47.20
27.02.24 / 50%
Target price
€82.92
27.02.25
Performance (%)
-59.11%
End price
€19.30
28.02.25
Summary
This prediction ended on 28.02.25 with a price of €19.30. Massive losses of -59.11% were the result for the BUY prediction by Guggenheim. Guggenheim has a follow-up prediction for Celldex Therapeutics where he still thinks Celldex Therapeutics is a Buy. Guggenheim has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Celldex Therapeutics 0.590% 0.590% 58.144%
iShares Core DAX® 0.855% 0.389% 2.533%
iShares Nasdaq 100 -0.989% -4.400% 25.154%
iShares Nikkei 225® -1.781% -11.216% 44.398%
iShares S&P 500 0.057% 0.778% 20.953%

Comments by Guggenheim for this prediction

In the thread Celldex Therapeutics diskutieren
Prediction Buy
Perf. (%) -59.11%
Target price 82.917
Change
Ends at 27.02.25

Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target raised by analysts at Guggenheim from $72.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for CLDX provided by MarketBeat

Guggenheim 
0
Report Share
27.02.24
In the thread Trading Celldex Therapeutics
Prediction Buy
Perf. (%) -59.11%
Target price 82.917
Change
Ends at 27.02.25

Die von Guggenheim gewählte maximale Laufzeit wurde überschritten

Guggenheim 
0
Report Share
28.02.25

Current prediction by Guggenheim for Celldex Therapeutics

buy
Celldex Therapeutics

Start price
Target price
Perf. (%)
€30.96
20.07.26
€87.40
20.07.27
-0.65%
24.07.26

Guggenheim 
20.07.26 50%